Advancing IgAN Care: Expert Strategies for Transformative Patient Outcomes

Discover the latest advances in IgA nephropathy (IgAN) treatments. Tune in for valuable insights from our experts!

Live Meeting
1.00 available credits
Information
May 25, 2024
13:45 - 14:45 CEST
Stockholmsmässan
Mässvägen 1 Älvsjö, 125 80 Stockholm, Sweden, Room: A2 + A3
ReachMD Healthcare Image
Please select your preferred calendar provider to add Advancing IgAN Care: Expert Strategies for Transformative Patient Outcomes to your calendar:
Details
Presenters
Comments
  • Overview

    Immunoglobulin A nephropathy (IgAN) is the leading cause of glomerulonephritis worldwide. Join renowned experts, Drs. Jürgen Floege, Khalil El Karoui, and Uyen Huynh-Do, as they use insightful case presentations to unravel the latest advances in IgAN treatments and describe innovative approaches to managing patients with IgAN.

    Click here to register for the ERA Congress.

  • Program Schedule*

    13:45    Welcome

    13:49    Panel Discussion: Navigating the Evolving Landscape of IgAN: From Current Standards to Real-World Application of Emerging Therapies

    14:00    Revolutionizing IgAN Care: A Patient-Centered Approach to Personalized Treatment and Improved Outcomes (Case Presentation)

    14:11    Panel Discussion: Exploring IgAN Treatment Strategies and Future Avenues

    14:22    Summary and Take-Home Messages

    14:32    Question & Answer Session

    14:45:   Adjourn

    *Subject to change

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Hosts:
    Jürgen Floege, MD
    Senior Professor
    RWTH Aachen University Hospital
    Aachen, Germany

    Dr. Floege has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AstraZeneca, Boehringer, Calliditas, Chinook, Novartis, Omeros, Roche, Stadapharm, Travere
    Other: Data Safety Monitoring Boards in studies of Novo Nordisk, Visterra

    Uyen Huynh-Do, MD
    Associate Professor
    Division of Nephrology & Hypertension
    Inselspital, University Hospital Bern
    Bern, Switzerland

    Dr. Huynh-Do hasreported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 

    Consulting Fees: Alexion, AstraZeneca, Boehringer, CSL Vifor, GSK, Novartis, Otsuka 
    Patent Holder: HemoTherapeutics 

    Faculty:
    Khalil El Karoui, MD, PhD
    Professor of Nephrology
    Tenon Hospital
    Sorbonne University
    Paris, France

    Dr. Karoui has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: CSL Vifor

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Howard Green has nothing to disclose. 
    • Hany Ibrahim, MD, has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Kathleen Sheridan, PhD, has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the benefits and limitations of the current standard of care for patients with IgA nephropathy (IgAN)
    • Analyze data from recent and ongoing IgAN clinical trials
    • Develop individualized treatment strategies to optimize outcomes in patients with IgAN
  • Target Audience

    This activity is designed to meet the educational needs of the practicing nephrologist.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Details
Presenters
Comments
  • Overview

    Immunoglobulin A nephropathy (IgAN) is the leading cause of glomerulonephritis worldwide. Join renowned experts, Drs. Jürgen Floege, Khalil El Karoui, and Uyen Huynh-Do, as they use insightful case presentations to unravel the latest advances in IgAN treatments and describe innovative approaches to managing patients with IgAN.

    Click here to register for the ERA Congress.

  • Program Schedule*

    13:45    Welcome

    13:49    Panel Discussion: Navigating the Evolving Landscape of IgAN: From Current Standards to Real-World Application of Emerging Therapies

    14:00    Revolutionizing IgAN Care: A Patient-Centered Approach to Personalized Treatment and Improved Outcomes (Case Presentation)

    14:11    Panel Discussion: Exploring IgAN Treatment Strategies and Future Avenues

    14:22    Summary and Take-Home Messages

    14:32    Question & Answer Session

    14:45:   Adjourn

    *Subject to change

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Hosts:
    Jürgen Floege, MD
    Senior Professor
    RWTH Aachen University Hospital
    Aachen, Germany

    Dr. Floege has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AstraZeneca, Boehringer, Calliditas, Chinook, Novartis, Omeros, Roche, Stadapharm, Travere
    Other: Data Safety Monitoring Boards in studies of Novo Nordisk, Visterra

    Uyen Huynh-Do, MD
    Associate Professor
    Division of Nephrology & Hypertension
    Inselspital, University Hospital Bern
    Bern, Switzerland

    Dr. Huynh-Do hasreported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 

    Consulting Fees: Alexion, AstraZeneca, Boehringer, CSL Vifor, GSK, Novartis, Otsuka 
    Patent Holder: HemoTherapeutics 

    Faculty:
    Khalil El Karoui, MD, PhD
    Professor of Nephrology
    Tenon Hospital
    Sorbonne University
    Paris, France

    Dr. Karoui has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: CSL Vifor

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Howard Green has nothing to disclose. 
    • Hany Ibrahim, MD, has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Kathleen Sheridan, PhD, has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the benefits and limitations of the current standard of care for patients with IgA nephropathy (IgAN)
    • Analyze data from recent and ongoing IgAN clinical trials
    • Develop individualized treatment strategies to optimize outcomes in patients with IgAN
  • Target Audience

    This activity is designed to meet the educational needs of the practicing nephrologist.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free